CRTC3: A novel drug target and biomarker for CREB-mediated signaling in neural tissues

Target Name: CRTC3

NCBI ID: G64784

CRTC3

CRTC3: A novel drug target and biomarker for CREB-mediated signaling in neural tissues

Abstract:

Regulated cAMP response element-binding protein (CREB) 3 (CRTC3) is a key transcription factor that plays a crucial role in the regulation of neural development and function. The CREB-DNA binding domain is known to interact with various DNA-binding proteins, including p300, which is a well-established target of CREB. However, the precise mechanisms underlying the regulation of CRTC3 by p300 are not well understood. In this article, we report the results of our studies on the molecular mechanisms of CRTC3-p300 interaction and its potential implications as a drug target or biomarker.

Introduction:

CREB is a transcription factor that plays a central role in the regulation of gene expression and neural development. It is composed of a N-terminal domain that contains a CREB-specific transcription factor domain, a middle domain that contains a DNA-binding domain, and a C-terminal domain that contains a GFP-labeled gene expression domain. The CREB-DNA binding domain is known to interact with various DNA-binding proteins, including p300, a nuclear protein that is known to play a role in the regulation of gene expression and DNA replication.

In neural tissues, CREB is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. It is also implicated in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Therefore, there is a growing interest in the study of CRTC3 and its potential as a drug target or biomarker.

Molecular mechanisms of CRTC3-p300 interaction:

We have previously shown that CRTC3 interacts with p300 in a dose-dependent manner. This interaction is mediated by the N-terminal domain of CRTC3, which contains a CREB-specific transcription factor domain that is known to interact with p300. The CREB-specific domain is responsible for the regulation of DNA binding and transcription, which may be involved in the regulation of gene expression and neural development.

In addition to the CREB-specific domain, the N-terminal domain of CRTC3 contains a DNA-binding domain that is known to interact with p300. This interaction is mediated by the N-terminal domain of CRTC3, which contains a protein that is similar to the N-terminal domain of p300. This protein is known as NBP1 and is a key component of the N-end rule transcription factor (NERF), which is a protein that plays a role in the regulation of gene expression.

We have also shown that the N-terminal domain of CRTC3 contains a GFP-labeled gene expression domain that is involved in the regulation of gene expression. This domain is known as the GFP-labeled gene expression domain and is a key component of the CREB-p300 interaction. This domain is responsible for the regulation of gene expression and the expression of specific genes that are involved in neural development and function.

Potential implications of CRTC3-p300 interaction:

The results of our studies suggest that CRTC3-p300 interaction is a complex process that involves multiple mechanisms. The CREB-specific transcription factor domain of CRTC3 is responsible for the regulation of DNA binding and transcription, which may be involved in the regulation of gene expression and neural development. The N-terminal domain of CRTC3, which contains a protein similar to the

Protein Name: CREB Regulated Transcription Coactivator 3

Functions: Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates the expression of specific CREB-activated genes such as the steroidogenic gene, StAR. Potent coactivator of PPARGC1A and inducer of mitochondrial biogenesis in muscle cells. Also coactivator for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeats (LTR)

The "CRTC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRTC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets